Management

  • Robert F. Johnston, Chairman of the Board and CEO
    • Johnston founded Johnston Associates, a venture capital firm, in 1968 to provide seed capital for start-ups emerging in the biotechnology and healthcare fields.
    • During his career, he founded numerous public companies including Sepracor (acquired by Dainippon Sumitomo Pharma Co), Cytogen (acquired by EUSA Pharma), I-STAT (acquired by Abbott), Genex and Envirogen (acquired by Shaw Environmental), and was instrumental in the early formation of many private companies such as Sonomed, Immunicon (acquired by J&J), PharmaStem (formerly Biocyte), Praelux (acquired by Amersham/GE) and Targent (acquired by Spectrum). Mr. Johnston served as CEO of Cytogen and Praelux (formerly SEQ).
    • Additionally, he is a member of the Advisory Council of the Department of Molecular Biology at Princeton University.
    • Johnston received his B.A. from Princeton University and his M.B.A. from New York University.
  • Gregg LaPointe, Director
    • Since 2012, Mr. Lapointe has served as Co-Founder and Chief Executive Officer of Cerium Pharmaceuticals, a privately-held biopharmaceutical company.
    • He previously held roles at Sigma-Tau Pharmaceuticals, Inc., a privately held biopharmaceutical company, from 2001 through 2012, including Chief Operating Officer from 2003 to 2008 and Chief Executive Officer from 2008 to 2012.
    • Mr. Lapointe previously served as a member of the Board of Directors of SciClone Pharmaceuticals, Inc., Raptor Pharmaceuticals, Inc., ImmunoCellular Therapeutics, Inc., Pharmaceutical Research Manufacturers of America (PhRMA) and Questcor Pharmaceuticals, Inc.
    • Mr. Lapointe has over a decade of experience in rare orphan drug issues with the FDA.
    • He currently serves on the Board of Directors of three public biopharmaceutical companies, Soligenix, Inc., Cytori Therapeutics, Inc., and Rigel Pharmaceuticals, Inc. In January 2019, Mr. LaPointe joined the board of Catabasis Pharmaceuticals, Inc. (Public company – rare disease in Duchenne Muscular Dystrophy).
    • He holds an MBA from Duke University, is a Certified Public Accountant, and holds a Bachelor of Commerce from Concordia University.
  • King C. Lee, Ph.D., R.A.C., Regulatory Consultant
    • Lee is an independent consultant, and most recently the VP of Regulatory/Clinical Affairs for Cornerstone Pharmaceuticals, Inc. Dr. Lee is also an adjunct professor of Quinnipiac University, and has been since 2006.
    • Previously, he was the VP of Regulatory Affairs for Acorda Therapeutics, Inc. and held management positions with ATON Pharma, Inc. (acquired by Merck in 2003), VION Pharmaceuticals, Inc. and Sterling-Winthrop.
    • He has authored and co-authored over 45 publications (scientific and professional papers, books and review articles) and over 45 scientific abstracts.
    • He received his Ph.D. in Pharmacology from the University of Kentucky and is certified by the Regulatory Affairs Professionals Board.